Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

6 marketed 4 in Phase 3 1 in Phase 2

This page covers all Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor, Mineralocorticoid receptor (MR), Beta-adrenergic receptors (propranolol); mineralocorticoid receptor (spironolactone).

Targets

Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor · Mineralocorticoid receptor (MR) · Beta-adrenergic receptors (propranolol); mineralocorticoid receptor (spironolactone) · Angiotensin-converting enzyme / Angiotensin II type 1 receptor + Mineralocorticoid receptor · Mineralocorticoid receptor

Marketed (6)

Ambrisentan plus Spironolactone · Brigham and Women's Hospital · Cardiovascular
Ambrisentan blocks endothelin-1 receptors to reduce pulmonary vascular resistance, while spironolactone is a mineralocorticoid receptor antagonist that provides additional hemodynamic and anti-fibrotic benefits.
Mineralocorticoid Receptor Antagonist · Cheng-Hsin General Hospital · Cardiovascular
Mineralocorticoid receptor antagonists block aldosterone signaling in the kidneys and other tissues, reducing sodium retention and potassium excretion.
Finerenone (BAY 94-8862) · University Medical Center Groningen · Cardiovascular, Nephrology
Finerenone is a non-steroidal mineralocorticoid receptor antagonist that blocks aldosterone signaling to reduce inflammation and fibrosis in the kidneys and cardiovascular system.
Propranolol - Spironolactone · University Hospital, Angers · Cardiovascular
This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and spironolactone (an aldosterone antagonist) to promote sodium and water excretion while retaining potassium.
Eplerenone (Night-time) · Vanderbilt University Medical Center · Cardiovascular
Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and other tissues, reducing sodium retention and potassium excretion.
ACEI / ARB+finerenone · Capital Institute of Pediatrics, China · Cardiovascular / Nephrology
This combination therapy blocks angiotensin II signaling via ACE inhibitors or ARBs while finerenone acts as a non-steroidal mineralocorticoid receptor antagonist to reduce kidney and cardiovascular injury.

Phase 3 pipeline (4)

Finerenone (BAY94-8862) · Bayer · Cardiovascular, Nephrology
Finerenone is a non-steroidal mineralocorticoid receptor antagonist that blocks aldosterone signaling to reduce inflammation and fibrosis in the kidneys and cardiovascular system.
Mineralocorticoid receptor antagonist potassium-canrenoate · University College, London · Cardiovascular
Potassium-canrenoate blocks mineralocorticoid receptors to reduce sodium reabsorption and potassium excretion in the kidney, lowering blood pressure and reducing fluid retention.
K-924 HD · Kowa Company, Ltd. · Cardiovascular
K-924 HD is a selective aldosterone antagonist that blocks mineralocorticoid receptor signaling to reduce sodium retention and blood pressure.
CS-3150 · Daiichi Sankyo Co., Ltd. · Cardiovascular
CS-3150 is a non-steroidal mineralocorticoid receptor (MR) antagonist that blocks aldosterone signaling to reduce sodium retention and blood pressure.

Phase 2 pipeline (1)

HF medication · Bayer · Cardiovascular
Blocks the action of aldosterone